Member Info for Sangijuelas1

You seem very impatient Dave and come across as very nervous.

I think this is a better article for potential new investors as the other is a bit dry

https://www.genengnews.com/on-your-radar/living-biotherapeutics-explore-new-niches/

Bermudashorts posted this on the other board,

https://www.europeanpharmaceuticalreview.com/article/164049/developing-and-delivering-live-biotherapeutic-products/

Thanks Lukin. No doubt we will still be here while others will have moved on

Right my comments were about 0518 and the vaccine program. That is where it's at for the company.

Not about Blautix.

My comments about funding were regarding Blautix and not the focus on the core programmes, which are funded in the short term.

The milestone payments for the vaccine programme are likely fairly trivial at this stage of development. So at this moment I don't think we can expect a sudden windfall, although that could be possible. Not enough info is available.

I was being sarcastic about the death spiral.

Dave, can you give me 1 example of a post I have made that is mindless ramping?

Thanks

The company has to start a P2 trial for 0518 with Bavencio and keep some cash for the Parkinsons trial.

This in addition to the ongoing 0518 Keytruda and analysing results of the asthma trial and the pancreatic cancer trial.

Well if your potential partner knows that you don't have the cash to develop the drug yourself, then they will take that into account when making an offer to license it from you.

Right, so I was responding to a post accusing me of market abuse for suggesting that they would need to raise capital for a Blautix trial by someone who stated that there's no indication whatsoever that they would need to raise capital until the end of 2022.

To address this point I highlighted DPs comments in the last presentation that they would consider the need for a raise early next year.

It seems that some people are very angry about the SP and like to take their anger out on someone who is not prepared to mindlessly ramp the stock based on magical thinking.

And Michael, if the potential licensing partner knows that they don't have cash to fund themselves then they are not going to get offered a good deal.

Michael, in the Jefferies presentation, which no doubt you didn't bother to watch, they said they would consider a fund raise in the early part of next year.

Here’s the link
https://wsw.com/webcast/jeff206/lbps/1850819?mobile=True

They are running multiple 0518 trials and due to start a large P2 in combination with Bavencio.

There's no cash for Blautix.

There's only so much a small biotech can do with limited resources.

They have stated that on multiple occasions.

That's why they have been discussing partnering since the initial Blautix results announcement.

The core focus is 0518. Nothing else matters at this stage.

Have Rog and Lee let you back into their Telegram group now?

A fund raise is not out of the question. Blautix P3 trial would cost at least £30m.

All the cash they have is earmarked for 0518 and the Parkinsons trial.

Some traders have bought in here and are desperately ramping to get their 10 per cent with talk of £2 by the end of the year.

Do not be fooled by their dribbling

They can't do anything with Blautix because they don't have the cash to run a P3 trial.

Anyone looking at a potential licensing deal know that a cash raise would be necessary and the dilution would be massive at the current price, so they won't put any kind of attractive offer on the table.

People are so desperate for this to go up 5p, look at the excitement yesterday about a 2p rise.

To any long term holders it just looks a bit sad and pathetic trying to entice the 5 per cent day traders.

Errr it's called not providing basic info to lazy Gammons that can't be bothered to read the company comms

April 2024 is the next update on Blautix

I mean completion dates for the 0518 Keytruda trial is down as Mar 23 and Mar 24 as primary completion dates.

So rather than wait until the end of the trial they are saying that they will likely register another trial for the patients with the right biomarkers much before the actual P3 would be due to start in 2-3 years time